Get access

Long-term outcome of ATG vs. Basiliximab induction

Authors

  • Frank Ulrich,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
    • Sebastian Niedzwiecki and Frank Ulrich contributed equally to this study.

  • Sebastian Niedzwiecki,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    2. Department of Endocrine, General and Vascular Surgery, Medical University of Lodz, Poland
    Search for more papers by this author
    • Sebastian Niedzwiecki and Frank Ulrich contributed equally to this study.

  • Andreas Pascher,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Sven Kohler,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Sascha Weiss,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Panagiotis Fikatas,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Guido Schumacher,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Gottfried May,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Petra Reinke,

    1. Department of Nephrology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Peter Neuhaus,

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
  • Stefan G. Tullius,

    1. Division of Transplant Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
    • Stefan Tullius and Johann Pratschke contributed equally to this study.

  • Johann Pratschke

    1. Department of Visceral, General and Transplantation Surgery, Charité Universitätsmedizin Berlin, Germany
    Search for more papers by this author
    • Stefan Tullius and Johann Pratschke contributed equally to this study.


  • [Correction added on 15 April 2011, after first online publication: the corresponding author was changed to Frank Ulrich.]

Frank Ulrich, MD, PhD, Head of Surgical Oncology and Kidney Transplantation, Dept. of General and Visceral Surgery, Clinical Center Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt Germany. Tel.: +49 (0)69 6301 5253; fax: +49 (0)69 6301 6211; e-mail: Frank.Ulrich@kgu.de

Abstract

Eur J Clin Invest 2011; 41 (9): 971–978

Abstract

Background  An evaluation of the long-term efficacy and incidence of adverse events after induction therapy with antithymocyte globulin (ATG) vs. Basiliximab in renal transplant patients.

Methods  Sixty recipients receiving ATG induction and a dual immunosuppression with Tacrolimus and steroids were compared retrospectively with 60 patients treated with Basiliximab. The following characteristics were evaluated: concomitant immunosuppression, recipient age, donor age, time on dialysis, cold ischemia time, year of transplantation and HLA mismatches.

Results  The 6-year patient survival in the ATG group was 91·7% compared to 85% in the Basiliximab group (not significant, n.s.). Graft survival at 6 years was 89·7% and. 83·6% in the ATG and the Basiliximab group (n.s.), respectively. Incidence of biopsy proven acute rejection episodes (33·3% vs. 26·7%) and delayed graft function (30% vs. 33·3%) were similar in both groups. Kidney function was not significantly different at 1 and 6 years. CMV infections were more prevalent in the ATG arm (22% vs. 5%; P = 0·05), and a significantly higher rate of haematological complications was observed following ATG induction.

Conclusions  ATG induction was associated with an improved (but n.s.) trend in patient and graft survival. Patients induced with ATG had a higher rate of CMV infections and haematological complications.

Ancillary